NICE fails to recommend nivolumab for lung cancer

16 December 2015

A ‘promising’ new treatment for lung cancer cannot be recommended for use in the NHS because it is not cost effective, the UK's National Institute for Health and Care Excellence (NICE) has said.

Nivolumab, marketed as Opdivo by Bristol-Myers Squibb (NYSE: BMY), has been hailed a cutting-edge cancer drug that has helped tumours vanish.

But the NICE has said the evidence provided by the company, together with its cost to the NHS – about £100,000 (~$150,000) per year per patient – has not allowed it to recommend nivolumab for routine use, over the current standard treatment docetaxel, which was first approved for use 17 years ago.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK